Cristina Simó

@mir.wustl.edu

Postdoctoral researcher, Mallinckrodt Institute of Radiology.
Washington University School of Medicine in St. Louis

Cristina Simó


                  Download Compact PDF  
https://researchid.co/simocosta
15

Scopus Publications

691

Scholar Citations

9

Scholar h-index

9

Scholar i10-index

Scopus Publications

  • MIB guides: [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging
    Cristina Simó, Alexander C. Vanover, E. Carmen Azevedo, Patrícia M. R. Pereira
    Molecular Imaging and Biology, 2025
  • Positron Emission Tomography and Optical Imaging to Monitor Bioorthogonal Diels-Alder Click Chemistry of Trastuzumab with a Porphyrin
    Sara R. D. Gamelas, Shayla Shmuel, Cristina Simó, Alex Vanover, João P. C. Tomé, Augusto C. Tomé, Leandro M. O. Lourenço, Patrícia M. R. Pereira
    Bioconjugate Chemistry, 2025
    Click chemistry to allow in vivo conjugation of a fluorophore porphyrin (Por)-tetrazine (Tz) with the human epidermal growth factor receptor 2 (HER2)-targeting trastuzumab conjugated with trans-cyclooctene (TCO) is described here. In vitro experiments confirmed successful click reactions between Por-Tz and trastuzumab-TCO and validated preserved trastuzumab immunoreactivity (no significant change in HER2 binding, p > 0.05). Positron emission tomography (PET) of [89Zr]Zr-DFO-trastuzumab-TCO demonstrated 17.1 ± 2.9% injected dose per gram of tumor at 48 h postinjection. Optical imaging showed an ∼10-fold increase in the click group for Por-Tz when compared with Por-Tz alone. This preclinical data demonstrate a pretargeted approach for dual PET and optical imaging of HER2-expressing tumors.
  • [64Cu]Cu-NOTA-Trastuzumab and [89Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression
    Cristina Simó, Shayla Shmuel, Alex Vanover, Patrícia M. R. Pereira
    Molecular Pharmaceutics, 2024
    Positron emission tomography (PET) has potential as a complementary technique to biomarker analysis, especially for human epidermal growth factor receptor 2 (HER2)-expressing tumors characterized by high heterogeneity. In this study, zirconium-89 (89Zr) and copper-64 (64Cu) labeled trastuzumab were employed to monitor varying levels of tumoral HER2 expression. Additionally, we studied the use of the cholesterol-depleting lovastatin as a pharmacological approach to enhance cell-surface HER2 expression in tumors with moderate to low HER2 levels, aiming to increase antibody accumulation in these tumor types. Both 89Zr- and 64Cu-labeled trastuzumab effectively monitor HER2 expression levels in xenografts exhibiting varying HER2 expression. No significant difference in tumor uptake was observed between 89Zr- or 64Cu-labeled trastuzumab, and tumor uptake for both radioimmunoconjugates positively correlated with HER2 protein levels. These findings underscore the potential of PET to monitor HER2 protein levels across heterogeneous tumors. Furthermore, our results suggest that further optimization of statin dosing and timing could offer a promising strategy to enhance trastuzumab accumulation in HER2-high, HER2-moderate, and HER2-low tumors.
  • Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
    Hyunsik Choi, Seung-hwan Jeong, Cristina Simó, Anna Bakenecker, Jordi Liop, Hye Sun Lee, Tae Yeon Kim, Cheol Kwak, Gou Young Koh, Samuel Sánchez, Sei Kwang Hahn
    Nature Communications, 2024
    Most non-muscle invasive bladder cancers have been treated by transurethral resection and following intravesical injection of immunotherapeutic agents. However, the delivery efficiency of therapeutic agents into bladder wall is low due to frequent urination, which leads to the failure of treatment with side effects. Here, we report a urease-powered nanomotor containing the agonist of stimulator of interferon genes (STING) for the efficient activation of immune cells in the bladder wall. After characterization, we perform in vitro motion analysis and assess in vivo swarming behaviors of nanomotors. The intravesical instillation results in the effective penetration and retention of nanomotors in the bladder. In addition, we confirm the anti-tumor effect of nanomotor containing the STING agonist (94.2% of inhibition), with recruitment of CD8+ T cells (11.2-fold compared with PBS) and enhanced anti-tumor immune responses in bladder cancer model in female mice. Furthermore, we demonstrate the better anti-tumor effect of nanomotor containing the STING agonist than those of the gold standard Bacille Calmette-Guerin therapy and the anti-PD-1 inhibitor pembrolizumab in bladder cancer model. Taken together, the urease-powered nanomotor would provide a paradigm as a next-generation platform for bladder cancer immunotherapy. Self-propelling micro/nanomotors represent a therapeutic option for drug delivery. Here the authors report the design and characterization of a biodegradable urease-powered nanomotor containing STING agonist, promoting anti-tumor immune responses in bladder cancer models.
  • Urease-powered nanobots for radionuclide bladder cancer therapy
    Cristina Simó, Meritxell Serra-Casablancas, Ana C. Hortelao, Valerio Di Carlo, Sandra Guallar-Garrido, Sandra Plaza-García, Rosa Maria Rabanal, Pedro Ramos-Cabrer, Balbino Yagüe, Laura Aguado, Lídia Bardia, Sébastien Tosi, Vanessa Gómez-Vallejo, Abraham Martín, Tania Patiño, Esther Julián, Julien Colombelli, Jordi Llop, Samuel Sánchez
    Nature Nanotechnology, 2024
    Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy.
  • Lipidomics and biodistribution of extracellular vesicles-secreted by hepatocytes from Zucker lean and fatty rats
    Maria Azparren‐Angulo, Justyna Mleczko, Oihane E. Alboniga, Sergei Kruglik, Jean‐Michel Guigner, Esperanza Gonzalez, Clara Garcia‐Vallicrosa, Jordi Llop, Cristina Simó, Cristina Alonso, Marta Iruarrizaga, Felix Royo, Juan M. Falcon‐Perez
    Journal of Extracellular Biology, 2024
    Extracellular vesicles (EVs) have been involved in metabolic syndrome, although their specific role in the development of the pathology is still unknown. To further study the role of EVs, we have analysed by Raman tweezers microspectroscopy and mass spectrometry‐based lipidomics the small EVs population secreted by fatty (ZF) and lean (ZL) hepatocytes obtained from Zucker rats. We have also explored in vivo and ex vivo biodistribution of these EVs through fluorine‐18‐radiolabelling using a positron emission tomography imaging. Based on the proportion of proteins to lipids and the types of lipids, our results indicate that within the range of small EVs, primary hepatocytes secrete different subpopulations of particles. These differences were observed in the enrichment of triglyceride species in EVs secreted by ZF hepatocytes. Biodistribution experiments showed accumulation in the brain, heart, lungs, kidney and specially in bladder after intravenous administration. In summary, we show that EVs released by a fatty hepatocytes carry a different lipid signature compared to their lean counterpart. Biodistribution experiment has shown no difference in the distribution of EVs secreted by ZF and ZL hepatocytes but has given us a first view of possible target organs for these particles. Our results might open a door to both pathology studies and therapeutic interventions.
  • A study of complexation and biological fate of polyethyleneimine-siRNA polyplexes in vitro and in vivo by fluorescence correlation spectroscopy and positron emission tomography imaging
    Tanja Ludtke, Cristina Simó, Santiago Gimenez Reyes, Marta Martinez Moro, Cristian Salvador, Hernan Ritacco, Patrizia Andreozzi, Jordi Llop, Sergio E. Moya
    Nanoscale, 2024
    Fluorescence correlation spectroscopy and positron emission tomography are used to study the formation of PEI siRNA polyplex nanoparticles and to trace their biological fate at cell level and in vivo.
  • PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET
    Dina Ibrahim, Cristina Simó, Emma L. Brown, Shayla Shmuel, Sandeep Surendra Panikar, Alex Benton, Rachel DeWeerd, Farrokh Dehdashti, Haeseong Park, Patrícia M. R. Pereira
    Frontiers in Immunology, 2024
    IntroductionThis study aimed to investigate the dynamics of programmed death-ligand 1 (PD-L1) expression, spatial heterogeneity, and binding affinity of FDA-approved anti-PD-L1 antibodies (avelumab and atezolizumab) in gastric cancer. Additionally, we determined how PD-L1 glycosylation impacts antibody accumulation in gastric cancer cells.MethodsDynamic PD-L1 expression was examined in NCIN87 gastric cancer cells. Comparative binding studies of avelumab and atezolizumab were conducted in gastric cancer models, both in vitro and in vivo. Antibody uptake in tumors was visualized through positron emission tomography (PET) imaging. PD-L1 glycosylation status was determined via Western blot analyses before and after PNGase F treatment. ResultsConsistent findings revealed time-dependent PD-L1 induction in NCIN87 gastric cancer cells and spatial heterogeneity in tumors, as shown by PET imaging and immunofluorescence. Avelumab displayed superior binding affinity to NCIN87 cells compared to atezolizumab, confirmed by in vivo PET imaging and ex vivo biodistribution analyses. Notably, PD-L1 glycosylation at approximately 50 kDa was observed, with PNGase F treatment inducing a shift to 35 kDa in molecular weight. Tissue samples from patient-derived xenografts (PDXs) validated the presence of both glycosylated and deglycosylated PD-L1 (degPD-L1) forms in gastric cancer. Immunofluorescence microscopy and binding assays demonstrated enhanced avelumab binding post-deglycosylation. DiscussionThis study provides an understanding of dynamic and spatially heterogeneous PD-L1 expression in gastric cancer. Anti-PD-L1 immunoPET was able to visualize gastric tumors, and PD-L1 glycosylation has significant implications for antibody recognition. These insights contribute to demonstrating the complexities of PD-L1 in gastric cancer, holding relevance for refining PD-L1 imaging-based approaches.
  • Positron Emission Tomography Studies of the Biodistribution, Translocation, and Fate of Poly Allyl Amine-Based Carriers for Sirna Delivery by Systemic and Intratumoral Administration
    Cristina Simo, Cristian Salvador, Patrizia Andreozzi, Vanessa Gomez‐Vallejo, Gabriela Romero, Damien Dupin, Jordi Llop, Sergio E. Moya
    Small, 2023
    Polyamine‐based vectors offer many advantages for gene therapy, but they are hampered by a limited knowledge on their biological fate and efficacy for nucleic acid delivery. The 18F radiolabeled siRNA is complexed with poly(allyl amine) hydrochloride (PAH), PEGylated PAH (PAHPEG), or oleic acid‐modified PAH (PAHOleic) to form polyplexes, and injected them intravenously into healthy rodents. The biodistribution patterns obtained by positron emission tomography (PET) imaging vary according to the polymer used for complexation. Free siRNA is quickly eliminated through the bladder. PAH and oleic acid modify PAH polyplexes accumulate in the lungs and liver. No elimination through the bladder is observed for PAH and PAHOleic within 2 h after administration. PAHPEG polyplexes accumulate in kidneys and are eliminated through the bladder. Polyplexes prepared with 18F‐labeled oleic acid‐modified PAH and non‐labeled siRNA show similar biodistribution to those prepared with labeled siRNA, but with more accumulation in the lungs due to the presence of non‐complexed polymer. Intravenous administration of PAHOleic polyplexes in tumor models results in a limited availability of siRNA. When PAHOleic polyplexes are administered intratumorally in tumor bearing rodents, ≈40% of the radioactivity is retained in the tumor after 180 min while free siRNA is completely eliminated.
  • Ammonium trifluoroborate-modified poly(β-aminoesters): A case study for PET-guided in vivo pharmacokinetic studies of a non-viral gene delivery system
    Raúl Cosialls, Odile Fernández, Cristina Simó, Krishna R. Pulagam, Marta Guerra-Rebollo, Jordi Llop, Cristina Fornaguera, Ana B. Cuenca, Salvador Borrós
    Journal of Controlled Release, 2023
  • PET Imaging of Self-Assembled 18F-Labelled Pd2L4 Metallacages for Anticancer Drug Delivery
    Raúl Cosialls, Cristina Simó, Salvador Borrós, Vanessa Gómez‐Vallejo, Claudia Schmidt, Jordi Llop, Ana B. Cuenca, Angela Casini
    Chemistry A European Journal, 2023
  • Novel Core–Shell Polyamine Phosphate Nanoparticles Self-Assembled from PEGylated Poly(allylamine hydrochloride) with Low Toxicity and Increased In Vivo Circulation Time
    Patrizia Andreozzi, Cristina Simó, Paolo Moretti, Joaquin Martinez Porcel, Tanja Ursula Lüdtke, Maria de los Angeles Ramirez, Lorenza Tamberi, Marco Marradi, Heinz Amenitsch, Jordi Llop, Maria Grazia Ortore, Sergio Enrique Moya
    Small, 2021
  • In Vivo Tracking of the Degradation of Mesoporous Silica through 89Zr Radio-Labeled Core–Shell Nanoparticles
    Elisa Bindini, Maria de los Angeles Ramirez, Xabier Rios, Unai Cossío, Cristina Simó, Vanessa Gomez‐Vallejo, Galo Soler‐Illia, Jordi Llop, Sergio E. Moya
    Small, 2021
  • Swarming behavior and in vivo monitoring of enzymatic nanomotors within the bladder
    Ana C. Hortelao, Cristina Simó, Maria Guix, Sandra Guallar-Garrido, Esther Julián, Diana Vilela, Luka Rejc, Pedro Ramos-Cabrer, Unai Cossío, Vanessa Gómez-Vallejo, Tania Patiño, Jordi Llop, Samuel Sánchez
    Science Robotics, 2021
  • Pre-targeting with ultra-small nanoparticles: Boron carbon dots as drug candidates for boron neutron capture therapy
    Irene V. J. Feiner, Krishna R. Pulagam, Kepa B. Uribe, Rossana Passannante, Cristina Simó, Kepa Zamacola, Vanessa Gómez-Vallejo, Natalia Herrero-Álvarez, Unai Cossío, Zuriñe Baz, María M. Caffarel, Charles H. Lawrie, Danielle J. Vugts, Luka Rejc, Jordi Llop
    Journal of Materials Chemistry B, 2021

RECENT SCHOLAR PUBLICATIONS

  • MIB guides: [ 89 Zr]Zr-DFO-trastuzumab and [ 64 Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging
    C Simó, AC Vanover, EC Azevedo, PMR Pereira
    Molecular imaging and biology 27 (4), 506-517 , 2025
    2025
    Citations: 1
  • PET imaging and optimization of HER2 modulation in HER2-low breast tumors to enhance therapeutic efficacy
    A Vanover, C Simó, A Benton, F Dehdashti, A Davis
    Journal of Nuclear Medicine 66 (supplement 1), 252245-252245 , 2025
    2025
  • Positron Emission Tomography and Optical Imaging to Monitor Bioorthogonal Diels–Alder Click Chemistry of Trastuzumab with a Porphyrin
    SRD Gamelas, S Shmuel, C Simó, A Vanover, JPC Tomé, AC Tomé, ...
    Bioconjugate Chemistry 36 (5), 1013-1020 , 2025
    2025
    Citations: 1
  • Click chemistry for theranostic approaches in triple negative breast cancer
    C Simo, S Shmuel, A Vanover, PM Pereira
    Cancer Research 85 (8_Supplement_1), 568-568 , 2025
    2025
  • Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
    H Choi, S Jeong, C Simó, A Bakenecker, J Liop, HS Lee, TY Kim, C Kwak, ...
    Nature communications 15 (1), 9934 , 2024
    2024
    Citations: 61
  • Re: Urease-Powered Nanobots for Radionuclide Bladder Cancer Therapy
    C Simo, M Serra-Casablancas, AC Hortelao
    JOURNAL OF UROLOGY 212 (5), 777-778 , 2024
    2024
  • [ 64 Cu]Cu-NOTA-Trastuzumab and [ 89 Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression
    C Simó, S Shmuel, A Vanover, PMR Pereira
    Molecular Pharmaceutics 21 (12), 6311-6322 , 2024
    2024
    Citations: 11
  • PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET
    D Ibrahim, C Simó, EL Brown, S Shmuel, SS Panikar, A Benton, ...
    Frontiers in immunology 15, 1405485 , 2024
    2024
    Citations: 13
  • Urease-powered nanobots for radionuclide bladder cancer therapy
    C Simó, M Serra-Casablancas, AC Hortelao, V Di Carlo, ...
    Nature Nanotechnology 19 (4), 554-564 , 2024
    2024
    Citations: 180
  • siRNA therapy against lung cancer via polyallylamine-oleic acid delivery system
    C Salvador Dittrich, C Simo, A Moncada, HJ Grande, J Llop, SE Moya, ...
    HUMAN GENE THERAPY 35 (3-4), A333-A334 , 2024
    2024
  • Lipidomics and biodistribution of extracellular vesicles‐secreted by hepatocytes from Zucker lean and fatty rats
    M Azparren‐Angulo, J Mleczko, OE Alboniga, S Kruglik, JM Guigner, ...
    Journal of extracellular biology 3 (2), e140 , 2024
    2024
    Citations: 5
  • Replication Data for: Urease-powered nanobots for radionuclide bladder cancer therapy
    C Simó, M Serra-Casablancas, AC Lopes Hortelão, V Di Carlo, ...
    2024
  • A study of complexation and biological fate of polyethyleneimine-siRNA polyplexes in vitro and in vivo by fluorescence correlation spectroscopy and positron emission tomography …
    T Ludtke, C Simó, SG Reyes, MM Moro, C Salvador, H Ritacco, ...
    Nanoscale 16 (7), 3525-3533 , 2024
    2024
    Citations: 2
  • Positron Emission Tomography Studies of the Biodistribution, Translocation, and Fate of Poly Allyl Amine-Based Carriers for Sirna Delivery by Systemic and Intratumoral …
    C Simo, C Salvador, P Andreozzi, V Gomez-Vallejo, G Romero, D Dupin, ...
    Small 20, 2304326 , 2023
    2023
    Citations: 6
  • Ammonium trifluoroborate-modified poly (β-aminoesters): A case study for PET-guided in vivo pharmacokinetic studies of a non-viral gene delivery system
    R Cosialls, O Fernandez, C Simo, KR Pulagam, M Guerra-Rebollo, J Llop, ...
    Journal of Controlled Release 358, 739-751 , 2023
    2023
    Citations: 6
  • Radionuclide therapy based on accumulated urease-powered nanobots in the bladder tumor of an orthotopic murine model
    C Simó, M Serra-Casablancas, A Hortelao, VD Carlo, S Guallar-Garrido, ...
    2023
  • PET Imaging of Self‐Assembled 18 F‐Labelled Pd 2 L 4 Metallacages for Anticancer Drug Delivery
    R Cosialls, C Simó, S Borrós, V Gómez‐Vallejo, C Schmidt, J Llop, ...
    Chemistry–A European Journal 29 (3), e202202604 , 2023
    2023
    Citations: 33
  • Novel Core–Shell Polyamine Phosphate Nanoparticles Self‐Assembled from PEGylated Poly (allylamine hydrochloride) with Low Toxicity and Increased In Vivo Circulation Time
    P Andreozzi, C Simó, P Moretti, JM Porcel, TU Lüdtke, MA Ramirez, ...
    Small 17 (35), 2102211 , 2021
    2021
    Citations: 26
  • In Vivo Tracking of the Degradation of Mesoporous Silica through 89 Zr Radio‐Labeled Core–Shell Nanoparticles
    E Bindini, MLA Ramirez, X Rios, U Cossío, C Simó, V Gomez‐Vallejo, ...
    Small 17 (30), 2101519 , 2021
    2021
    Citations: 49
  • Swarming behavior and in vivo monitoring of enzymatic nanomotors within the bladder
    AC Hortelao, C Simó, M Guix, S Guallar-Garrido, E Julián, D Vilela, L Rejc, ...
    Science Robotics 6 (52), eabd2823 , 2021
    2021
    Citations: 243

MOST CITED SCHOLAR PUBLICATIONS

  • Swarming behavior and in vivo monitoring of enzymatic nanomotors within the bladder
    AC Hortelao, C Simó, M Guix, S Guallar-Garrido, E Julián, D Vilela, L Rejc, ...
    Science Robotics 6 (52), eabd2823 , 2021
    2021
    Citations: 243
  • Urease-powered nanobots for radionuclide bladder cancer therapy
    C Simó, M Serra-Casablancas, AC Hortelao, V Di Carlo, ...
    Nature Nanotechnology 19 (4), 554-564 , 2024
    2024
    Citations: 180
  • Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy
    H Choi, S Jeong, C Simó, A Bakenecker, J Liop, HS Lee, TY Kim, C Kwak, ...
    Nature communications 15 (1), 9934 , 2024
    2024
    Citations: 61
  • In Vivo Tracking of the Degradation of Mesoporous Silica through 89 Zr Radio‐Labeled Core–Shell Nanoparticles
    E Bindini, MLA Ramirez, X Rios, U Cossío, C Simó, V Gomez‐Vallejo, ...
    Small 17 (30), 2101519 , 2021
    2021
    Citations: 49
  • Pre-targeting with ultra-small nanoparticles: Boron carbon dots as drug candidates for boron neutron capture therapy
    IVJ Feiner, KR Pulagam, KB Uribe, R Passannante, C Simó, K Zamacola, ...
    Journal of Materials Chemistry B 9 (2), 410-420 , 2021
    2021
    Citations: 46
  • PET Imaging of Self‐Assembled 18 F‐Labelled Pd 2 L 4 Metallacages for Anticancer Drug Delivery
    R Cosialls, C Simó, S Borrós, V Gómez‐Vallejo, C Schmidt, J Llop, ...
    Chemistry–A European Journal 29 (3), e202202604 , 2023
    2023
    Citations: 33
  • Novel Core–Shell Polyamine Phosphate Nanoparticles Self‐Assembled from PEGylated Poly (allylamine hydrochloride) with Low Toxicity and Increased In Vivo Circulation Time
    P Andreozzi, C Simó, P Moretti, JM Porcel, TU Lüdtke, MA Ramirez, ...
    Small 17 (35), 2102211 , 2021
    2021
    Citations: 26
  • PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET
    D Ibrahim, C Simó, EL Brown, S Shmuel, SS Panikar, A Benton, ...
    Frontiers in immunology 15, 1405485 , 2024
    2024
    Citations: 13
  • [ 64 Cu]Cu-NOTA-Trastuzumab and [ 89 Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression
    C Simó, S Shmuel, A Vanover, PMR Pereira
    Molecular Pharmaceutics 21 (12), 6311-6322 , 2024
    2024
    Citations: 11
  • Monitoring the collective behavior of enzymatic nanomotors in vitro and in vivo by PET-CT
    AC Hortelao, C Simó, M Guix, S Guallar-Garrido, E Julián, D Vilela, L Rejc, ...
    bioRxiv, 2020.06. 22.146282 , 2020
    2020
    Citations: 8
  • Positron Emission Tomography Studies of the Biodistribution, Translocation, and Fate of Poly Allyl Amine-Based Carriers for Sirna Delivery by Systemic and Intratumoral …
    C Simo, C Salvador, P Andreozzi, V Gomez-Vallejo, G Romero, D Dupin, ...
    Small 20, 2304326 , 2023
    2023
    Citations: 6
  • Ammonium trifluoroborate-modified poly (β-aminoesters): A case study for PET-guided in vivo pharmacokinetic studies of a non-viral gene delivery system
    R Cosialls, O Fernandez, C Simo, KR Pulagam, M Guerra-Rebollo, J Llop, ...
    Journal of Controlled Release 358, 739-751 , 2023
    2023
    Citations: 6
  • Lipidomics and biodistribution of extracellular vesicles‐secreted by hepatocytes from Zucker lean and fatty rats
    M Azparren‐Angulo, J Mleczko, OE Alboniga, S Kruglik, JM Guigner, ...
    Journal of extracellular biology 3 (2), e140 , 2024
    2024
    Citations: 5
  • A study of complexation and biological fate of polyethyleneimine-siRNA polyplexes in vitro and in vivo by fluorescence correlation spectroscopy and positron emission tomography …
    T Ludtke, C Simó, SG Reyes, MM Moro, C Salvador, H Ritacco, ...
    Nanoscale 16 (7), 3525-3533 , 2024
    2024
    Citations: 2
  • MIB guides: [ 89 Zr]Zr-DFO-trastuzumab and [ 64 Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging
    C Simó, AC Vanover, EC Azevedo, PMR Pereira
    Molecular imaging and biology 27 (4), 506-517 , 2025
    2025
    Citations: 1
  • Positron Emission Tomography and Optical Imaging to Monitor Bioorthogonal Diels–Alder Click Chemistry of Trastuzumab with a Porphyrin
    SRD Gamelas, S Shmuel, C Simó, A Vanover, JPC Tomé, AC Tomé, ...
    Bioconjugate Chemistry 36 (5), 1013-1020 , 2025
    2025
    Citations: 1
  • PET imaging and optimization of HER2 modulation in HER2-low breast tumors to enhance therapeutic efficacy
    A Vanover, C Simó, A Benton, F Dehdashti, A Davis
    Journal of Nuclear Medicine 66 (supplement 1), 252245-252245 , 2025
    2025
  • Click chemistry for theranostic approaches in triple negative breast cancer
    C Simo, S Shmuel, A Vanover, PM Pereira
    Cancer Research 85 (8_Supplement_1), 568-568 , 2025
    2025
  • Re: Urease-Powered Nanobots for Radionuclide Bladder Cancer Therapy
    C Simo, M Serra-Casablancas, AC Hortelao
    JOURNAL OF UROLOGY 212 (5), 777-778 , 2024
    2024
  • siRNA therapy against lung cancer via polyallylamine-oleic acid delivery system
    C Salvador Dittrich, C Simo, A Moncada, HJ Grande, J Llop, SE Moya, ...
    HUMAN GENE THERAPY 35 (3-4), A333-A334 , 2024
    2024